Accueil   Diary - News   All news Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020

Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020

Poxel dresse un bilan de ses activités et publie sa position de trésorerie et son chiffre d’affaires du troisième trimestre et des neuf premiers mois de 2020

 

  • Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of type 2 diabetes in July 2020 and a target launch is expected in fiscal year 2021 ; a milestone payment of EUR 4 million was received in Q3 2020 from Sumitomo Dainippon Pharma
  • Imeglimin Phase 3 TIMES results were presented at the 56 th European Association for the Study of Diabetes (EASD) meeting; Phase 2b, Phase 3 TIMES results, and additional safety data were presented at the 63 rd Annual Meeting of Japanese Diabetes Society (JDS)
  • PXL770 Phase 2a trial for the treatment of NASH met its primary efficacy endpoint and trial objectives, and it was observed to be safe and well tolerated
  • PXL770 profile supports development in NASH and also further evaluation for combination use, as well as utility of adenosine monophosphate-activated protein kinase (AMPK) activation in other chronic and rare metabolic diseases
  •  PXL065 Phase 2 trial was initiated in biopsy-proven NASH patients in September 2020; streamlined development with a single Phase 2 trial given knowledge of pioglitazone, including data in NASH, and 505(b)(2) regulatory pathway, which offers the opportunity for an efficient and lower risk development program
  • As of September 30, 2020, cash and cash equivalents were EUR 41.5 million (USD 48.6 million)

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today provided a corporate update and announced its cash position and revenue for the third quarter and the nine months ended September 30, 2020.

 

Read the press release